Business context and reporting period
The supplied filing is Sevion Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended December 31, 2015, covering its fiscal second quarter and first six months of fiscal 2016 (fiscal year ending June 30). It is not identified as a filing by Eloxx Pharmaceuticals, Inc.; verify that this is the intended filing.
Sevion was a development-stage biotechnology company pursuing antibody therapeutics for cancer and immunological diseases. Its lead candidates included SVN001 and SVN002. Management said research spending on its antibody program had been reduced pending a strategic or financing transaction.
Key financial metrics
| Metric | Three months ended Dec. 31, 2015 | Six months ended Dec. 31, 2015 | Comparison |
|---|---|---|---|
| Licensing revenue | $37,500 | $75,000 | $0 in the comparable 2014 periods |
| Operating loss | $3.76 million | $4.91 million | 2014: $10.75 million and $15.93 million |
| Net loss | $3.86 million | $4.04 million | 2014: $10.75 million and $15.93 million |
| Loss per common share | $0.19 | $0.21 | 2014: $0.78 and $1.15 |
| Research and development expense | $595,000 | $1.20 million | Down 56.6% and 65.8%, respectively, year over year |
| General and administrative expense | $401,000 | $988,000 | Down 68.0% and 51.3%, respectively, year over year |
For the six months, operating cash use was $2.12 million, investing cash flow was zero, and financing provided $1.15 million. Cash declined $968,053 to $2.37 million. At December 31, current assets were $2.69 million, current liabilities $569,155, and working capital $2.12 million. Total liabilities were $6.92 million, including $2.33 million of warrant and stock-right liabilities and a $3.92 million deferred tax liability; the filing does not show conventional borrowings. No gross margin is presented.
Changes, outlook, and risks
- Losses decreased substantially year over year, primarily because of reduced R&D, closure of the New Jersey office, and staff reductions—not because of material revenue growth. Revenue was limited to amortization of deferred collaboration revenue.
- The company recorded a $2.8 million goodwill impairment in the quarter after a decline in market value. Goodwill was $2.98 million at period-end; acquired research and development of $9.8 million was not impaired. The 2014 comparison included an $8.12 million goodwill impairment and $2.29 million patent write-off.
- Management estimated cash would fund operations through at least June 30, 2016, but said additional capital was needed. Planned funding sources included equity or debt, strategic transactions, and licensing; there was no assurance financing would be available on acceptable terms. Failure to raise funds could force program cuts, licensing, a sale, cessation of operations, or bankruptcy.
- A Janssen-affiliate collaboration provided upfront and research-support payments; Sevion could potentially receive development and commercial milestones totaling up to $125 million plus low-single-digit royalties if candidates are licensed and milestones achieved. These amounts are contingent, not current revenue or assured proceeds.
- Disclosure controls and internal control over financial reporting were deemed ineffective due to an unremediated material weakness in review and calculation of equity-linked instruments; management reported a material financial-statement adjustment. This is a significant reporting risk.
- Other material risks include recurring losses and going-concern uncertainty, dependence on external financing and research partners, clinical and regulatory uncertainty, intellectual-property risks, and potential shareholder dilution. Outstanding warrants, options, and convertible preferred stock could materially increase shares outstanding.
Important facts to verify
- Confirm the intended issuer: this document names Sevion Therapeutics, not Eloxx Pharmaceuticals.
- Verify the reported cash runway and financing needs against subsequent filings and financing events.
- Check progress in remediating the equity-linked-instrument control weakness and any later corrections or restatements.
- Review the terms, status, and contingent economics of the Janssen collaboration and any subsequent licensing milestones.
- Assess potential dilution from warrants, options, and preferred-stock conversion, including any exercise-price or anti-dilution provisions.